New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
08:06 EDTAMRNAmarin announces notification of additional U.S. patent allowance
Amarin Corporation announced that the United States Patent and Trademark Office, or USPTO, has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/272,520 titled "Compositions and Methods for Lowering Triglycerides." This application includes claims intended to protect the proposed Vascepa indication based on Amarin's Phase 3 ANCHOR clinical trial results. Amarin is on track to file a Supplemental New Drug Application for the Vascepa ANCHOR indication with the FDA by the end of February, and expects an FDA action date on the application before the end of 2013. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, after issuance of the patent and approval of Vascepa in the ANCHOR indication. The claims in this allowed application cover a method of use relating to Vascepa's ANCHOR indication. Specifically, the allowed independent claims covers use of about 4 grams per day of highly pure icosapent ethyl, or EPA, including Vascepa, to lower triglycerides and LDL-C.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
16:29 EDTAMRNOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:31 EDTAMRNAmarin granted summary judgment motion in suit against FDA over Vascepa
Subscribe for More Information
13:36 EDTAMRNAmarin surges after court sides with company on Vascepa exclusivity
Shares of Amarin Pharmaceuticals are surging higher after a U.S. district court sided with the company in its challenge of the Food and Drug Administrationís determination that Amarinís new drug, Vascepa, is not entitled to a five-year period of market exclusivity under the Federal Food, Drug, and Cosmetic Act. The court granted the company's motion for summary judgment and the decision denying Amarinís claim for exclusivity was vacated. The matter was remanded to the FDA for proceedings consistent with the court's opinion. In afternoon trading, Amarin shares jumped as high as $2.80 and are now up 22.5% to $2.39.
13:29 EDTAMRNAmarin wins district court ruling on Vascepa exclusivity
Amarin shares jumped 31% following the ruling.
May 22, 2015
10:32 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held in New York on May 27 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use